Premium
Debrisoquin oxidation polymorphism in a Spanish population
Author(s) -
Benítez Julio,
LLerena Adrián,
Cobaleda Jesús
Publication year - 1988
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1988.115
Subject(s) - urine , metabolite , population , biology , pharmacogenetics , pharmacology , medicine , genetics , genotype , gene , environmental health
The capacity for debrisoquin metabolism was determined in 377 healthy Spanish volunteers by measuring the amount of debrisoquin and its main metabolite, 4‐hydroxydebrisoquin, in urine after an oral dose of debrisoquin. Debrisoquin oxidation was polymorphic, with 25 subjects (6.6%) phenotyped as poor metabolizers whereas 352 subjects (93.4%) were classified as extensive metabolizers. The metabolic ratio between debrisoquin and 4‐hydroxydebrisoquin (percent of dose) in 6‐hour urine samples ranged from 0.03 in extensive metabolizers to 93.5 in poor metabolizers. The proportion of poor metabolizers found is in the range observed in other white populations studied. Clinical Pharmacology and Therapeutics (1988) 44, 74–76; doi: 10.1038/clpt.1988.115